RL_sparky
Senior Member
- Messages
- 379
- Location
- California
Chimerix Inc. CMRX-81.61% said Monday that the Phase 3 trial of a drug used to prevent infections following blood and marrow transplants didn’t meet its goals.
"The company’s drug brincidofovir failed to prevent cytomegalovirus infections 24 weeks after patients received hematopoietic cell transplants, which help restore marrow and immunity functionality. Consistent with the 2013 Phase 2 trial, the drug did reduce infection rates after 14 weeks of treatment. However, in the next 10 weeks, after treatment was stopped, there was an increase in infections and a “non-statistically significant increase in mortality” compared with the control group".
http://www.wsj.com/articles/chimerix-shares-plunge-after-late-stage-trial-fails-1451309865
http://www.marketwatch.com/story/chimerix-shares-crater-after-late-stage-trial-fails-2015-12-28
"The company’s drug brincidofovir failed to prevent cytomegalovirus infections 24 weeks after patients received hematopoietic cell transplants, which help restore marrow and immunity functionality. Consistent with the 2013 Phase 2 trial, the drug did reduce infection rates after 14 weeks of treatment. However, in the next 10 weeks, after treatment was stopped, there was an increase in infections and a “non-statistically significant increase in mortality” compared with the control group".
http://www.wsj.com/articles/chimerix-shares-plunge-after-late-stage-trial-fails-1451309865
http://www.marketwatch.com/story/chimerix-shares-crater-after-late-stage-trial-fails-2015-12-28